JaLCDOI 10.18926/AMO/60796
FullText URL 74_5_371.pdf
Author Makimoto, Go| Ohashi, Kadoaki| Maeda, Yoshinobu| Kiura, Katsuyuki|
Abstract The prognosis of advanced non-small cell lung cancer (NSCLC) patients has improved in recent decades, especially for patients with an oncogenic driver mutation. Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are effective for patients with the echinoderm microtubule-associated protein-like 4-ALK fusion gene. Several ALK-TKIs have been established: the first-generation ALK-TKI, crizotinib; second-generation ALK-TKIs, alectinib and ceritinib; and third-generation ALK-TKI, lorlatinib. Some ALK-TKIs are effective for tumors that are resistant to other ALK-TKIs; however, as is known in epidermal growth factor receptormutant lung cancer, tumor resistance is inevitable. ALK-positive NSCLCs acquire resistance via various mechanisms, making it a heterogeneous disease. Therefore, it is necessary to develop next-generation treatment strategies, such as the use of next-generation ALK-TKIs for secondary mutations, or combination therapies with ALK-TKIs and other TKIs. In this review, we summarize the development and use of ALK-TKIs, prior pivotal clinical trials, and resistance mechanisms.
Keywords lung cancer anaplastic lymphoma kinase tyrosine kinase inhibitors resistance mechanism
Amo Type Review
Published Date 2020-10
Publication Title Acta Medica Okayama
Volume volume74
Issue issue5
Publisher Okayama University Medical School
Start Page 371
End Page 379
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2020 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 33106692
Web of Science KeyUT 000581970100001
NAID 120006892922
JaLCDOI 10.18926/AMO/60802
FullText URL 74_5_423.pdf
Author Hirabae, Atsuko| Ichihara, Eiki| Sunami, Ryota| Ota, Moeko| Iwamoto, Yoshitaka| Maeda, Yoshinobu| Kiura, Katsuyuki|
Abstract We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.
Keywords lung cancer immune checkpoint inhibitors pembrolizumab hyperprogression
Amo Type Case Report
Published Date 2020-10
Publication Title Acta Medica Okayama
Volume volume74
Issue issue5
Publisher Okayama University Medical School
Start Page 423
End Page 425
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2020 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 33106698
Web of Science KeyUT 000581970100007
NAID 120006892928
Author Nishii, Kazuya| Ohashi, Kadoaki| Tamura, Tomoki| Ninomiya, Kiichiro| Matsubara, Takehiro| Senoo, Satoru| Kano, Hirohisa| Watanabe, Hiromi| Oda, Naohiro| Makimoto, Go| Higo, Hisao| Kato, Yuka| Ninomiya, Takashi| Kubo, Toshio| Yamamoto, Hiromasa | Tomida, Shuta| Hotta, Katsuyuki| Tabata, Masahiro| Toyooka, Shinichi| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords non-small cell lung cancer epidermal growth factor receptor mutations droplet digital PCR exhaled breath condensate EGFR-TKIs
Note This fulltext is available in Apr. 2021.|
Published Date 2020-12
Publication Title Oncology Letters
Volume volume20
Issue issue6
Publisher Spandidos Publications
Start Page 393
ISSN 1792-1074
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
File Version publisher
PubMed ID 33193853
DOI 10.3892/ol.2020.12256
Web of Science KeyUT 000595649300005
Related Url isVersionOf https://doi.org/10.3892/ol.2020.12256
FullText URL fulltext.pdf
Author Ichihara, Eiki| Miyahara, Nobuaki| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords lung cancer interstitial pneumonia
Published Date 2020-01-15
Publication Title Internal Medicine
Volume volume59
Issue issue2
Publisher 日本内科学会
Start Page 163
End Page 167
ISSN 0918-2918
NCID AA10827774
Content Type Journal Article
language 英語
Copyright Holders © 2020 by The Japanese Society of Internal Medicine
File Version publisher
PubMed ID 31534086
NAID 130007785095
DOI 10.2169/internalmedicine.3481-19
Web of Science KeyUT 000507577600002
Related Url isVersionOf https://doi.org/10.2169/internalmedicine.3481-19
FullText URL fulltext.pdf
Author Sugiura, Hiroyuki| Nishimori, Hisakazu| Nishii, Kazuya| Toji, Tomohiro| Fujii, Keiko| Fujii, Nobuharu| Matsuoka, Ken-ichi| Nakata, Koh| Kiura, Katsuyuki| Maeda, Yoshinobu|
Keywords pulmonary alveolar proteinosis primary myelofibrosis autopsy ruxolitinib
Published Date 2020-08-15
Publication Title Internal Medicine
Volume volume59
Issue issue16
Start Page 2023
End Page 2028
ISSN 0918-2918
NCID AA10827774
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2020 by The Japanese Society of Internal Medicine
File Version publisher
PubMed ID 32448830
DOI 10.2169/internalmedicine.4082-19
Web of Science KeyUT 000563078400014
Related Url isVersionOf https://doi.org/10.2169/internalmedicine.4082-19
FullText URL fulltext.pdf
Author Nishii, Kazuya| Inoue, Masaaki| Obata, Hideto| Ueda, Yutaka| Kozuki, Toshiyuki| Yamasaki, Masahiro| Moritaka, Tomonori| Awaya, Yoshikazu| Sugimoto, Keisuke| Gemba, Kenichi| Kuyama, Shoichi| Ichikawa, Hirohisa| Shibayama, Takuo| Kubota, Tetsuya| Kodani, Masahiro| Kishino, Daizo| Fujimoto, Nobukazu| Ishikawa, Nobuhisa| Tsubata, Yukari| Ishii, Tomoya| Fujitaka, Kazunori| Hotta, Katsuyuki| Kiura, Katsuyuki|
Keywords Database observational study real world data surveillance treatment
Published Date 2021-01-12
Publication Title Thoracic Cancer
Publisher Wiley
ISSN 1759-7706
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2020 The Authors.
File Version publisher
PubMed ID 33434415
DOI 10.1111/1759-7714.13789
Web of Science KeyUT 000606961500001
Related Url isVersionOf https://doi.org/10.1111/1759-7714.13789
FullText URL fulltext.pdf
Author Harada, Daijiro| Isozaki, Hideko| Kozuki, Toshiyuki| Yokoyama, Toshihide| Yoshioka, Hiroshige| Bessho, Akihiro| Hosokawa, Shinobu| Takata, Ichiro| Takigawa, Nagio| Hotta, Katsuyuki| Kiura, Katsuyuki| Okayama Lung Cancer Study Group|
Keywords Alectinib anaplastic lymphoma kinase crizotinib drug therapy non-small cell lung carcinoma
Published Date 2021-01-20
Publication Title Thoracic Cancer
Publisher Wiley
ISSN 1759-7706
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2021 The Authors.
File Version publisher
PubMed ID 33470536
DOI 10.1111/1759-7714.13825
Web of Science KeyUT 000608856400001
Related Url isVersionOf https://doi.org/10.1111/1759-7714.13825
JaLCDOI 10.18926/AMO/61429
FullText URL 75_1_15.pdf
Author Katsui, Kuniaki| Ogata, Takeshi| Tada, Akihiro| Sugiyama, Soichi| Yoshio, Kotaro| Kuroda, Masahiro| Kiura, Katsuyuki| Maeda, Yoshinobu| Toyooka, Shinichi| Hiraki, Takao| Kanazawa, Susumu|
Abstract The aim of this study was to investigate whether volumetric positron emission tomography (PET) parameters are prognostic predictors in stage III non-small cell lung cancer patients receiving definitive concurrent chemo-radiotherapy (CCRT) with cisplatin/docetaxel. Cases involving definitive CCRT were reviewed retrospectively, and the maximum standardized uptake value, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated. The relationships between these PET parameters and prognosis were analyzed. MTV and TLG were significant predictors of distant metastasis-free survival (DMFS) (p = 0.0003 and 0.0005, respectively) and progression-free survival (PFS) (p = 0.001 and 0.0007, respectively). The three-year DMFS rates in patients with low and high MTV were 13.3% and 64.6%, respectively, and the corresponding values in those with low and high TLG were 13.3% and 65.2%, respectively. The three-year PFS rates in patients with low and high MTV were 13.3% and 57.8%, respectively, and the corresponding values in patients with low and high TLG were 13.3% and 57.8%, respectively. However, MTV and TLG were not predictors of local control or overall sur-vival. We demonstrated that volumetric PET parameters were predictors of patients receiving definitive CCRT. Our findings contradict the findings of previous reports and warrant further research to validate them.
Keywords volumetric positron emission tomography parameters distant metastasis-free survival chemoradiotherapy cisplatin/docetaxel non-small cell lung cancer
Amo Type Original Article
Published Date 2021-02
Publication Title Acta Medica Okayama
Volume volume75
Issue issue1
Publisher Okayama University Medical School
Start Page 15
End Page 23
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2021 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 33649609